CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
November 20, 2019 21:18 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
November 19, 2019 16:14 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for...
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
November 19, 2019 07:00 ET
|
CRISPR Therapeutics AG
-Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
October 28, 2019 07:00 ET
|
CRISPR Therapeutics AG
-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Began treating patients in Phase 1/2 clinical trial of CTX110™, targeting...
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
October 15, 2019 07:00 ET
|
CRISPR Therapeutics AG
- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous...
CRISPR Therapeutics to Present at Upcoming Investor Conferences
October 01, 2019 07:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019
September 17, 2019 07:00 ET
|
CRISPR Therapeutics AG
-New data demonstrate successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells- ZUG, Switzerland, CAMBRIDGE, Mass., and SAN DIEGO, Sept. 17, 2019 ...
CRISPR Therapeutics to Present at Upcoming Investor Conferences
July 31, 2019 07:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
July 29, 2019 16:01 ET
|
CRISPR Therapeutics AG
-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110™, targeting CD19+ malignancies- ...
CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes
July 01, 2019 16:01 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...